Searched for
BIOCON BIOLOGICS INVESTMENT
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- Biocon Biologics refinances 1.1 billion debt through US dollar bonds and new syndicated facilityThe bonds will be issued by Biocon Biologics Global plc which is a wholly owned subsidiary of BBL and will be backed by a strong security p...
- Competition Commission of India clears Kotak-Biocon Biologics dealThe investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.
- Biocon Biologics may raise additional equity of $300 million in FY24 to pare debtBiocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...
- Serum Institute to double investment in Biocon Biologics to $300 millionSerum Institute of Life Sciences (SILS) has converted a $150 million loan into equity, increasing its investment in Biocon Biologics. This ...
- India's Serum to double investment in Biocon's unit to $300 mlnSerum Institute of Life Sciences is a unit of Serum Institute of India, the world's biggest vaccine maker. Under new terms of the alliance,...
- Biocon completes $3.34 billion acquisition of Viatris's biosimilar businessTo fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...
- Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar businessThe transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...
- Biocon gains 2% as arm receives Rs 555 crore equity investment from ADQKiran Mazumdar-Shaw, Executive Chairperson at Biocon in a company filing to BSE said, "We welcome ADQ as our investment partner as we pursu...
- Abu Dhabi-based ADQ picks up minority stake in Biocon Biologics for $75 millionThe transaction values Biocon Biologics at $4.17 billion, said the company in a press release.
- Biocon Biologics approves primary equity investment by ADQ worth Rs 555 croreAs per the terms of the proposed agreement, ADQ will invest Rs 555 Crore for a 1.80 per cent minority stake in the biosimilar business, val...
- Biocon Biologics to receive $150 million from Goldman Sachs against convertible debentures“The Board of its (Biocon’s) subsidiary Biocon Biologics has approved a Rs 1,125 Crore ($150 million) capital injection from Goldman Sachs....
- Tata Capital picks up 0.85% stake in Biocon Biologics for $30 millionPost the completion of this transaction, Biocon will hold a 95.25 per cent stake in Biocon Biologics.
- Biocon Biologics eyes $200m, plans IPO in 2 years: Mazumdar-ShawIt looks to build a pipeline of 28 biosimilars across global markets in three phases.
- True North to acquire 2.4% stake in Biocon BiologicsDeal values Biocon Biologics at $3 billion
- True North buys into Biocon Biologics, deal values firm at around $3.5 billionTrue North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...
- Temasek, TrueNorth-CPPIB seek to invest in Biocon BiologicsEye minority stake in Biocon Biologics; unit may be valued at $4 billion, higher than the market cap of Biocon.
Load More
